Intestinal function is impaired in patients with Chronic Obstructive Pulmonary Disease

S.K. Kirschner, N.E.P. Deutz, R. Jonker, S.W.M.O. Damink, R.I. Harrykissoon, A.J. Zachria, S. Dasarathy, M.P.K.J. Engelen*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Web of Science)

Abstract

Background & aims: Gastrointestinal symptoms are prevalent extrapulmonary systemic manifestations of Chronic Obstructive Pulmonary Disease (COPD), but have been rarely studied. We dissected the perturbations in intestinal function in human patients with COPD using comprehensive metabolic and physiological approaches. Methods: In this observational study, small intestinal membrane integrity and active carrier-mediated glucose transport were quantified by sugar permeability test in 21 clinically stable patients with moderate to severe COPD (mean FEV1, 41.2 (3.2) % of predicted) and 16 healthy control subjects. Protein digestion and absorption was analyzed using stable tracer kinetic methods. Plasma acetate, propionate, and butyrate concentrations were measured as markers of intestinal microbial metabolism. Results: Compared with healthy controls, non carrier-mediated permeability was higher (0.062 (95% CI [0.046, 0.078]) vs. 0.037 (95% CI [0.029, 0.045]), P = 0.009) and active glucose transport lower in COPD (31.4 (95% CI [23.4, 39.4])% vs. 48.0 (95% CI [37.8, 58.3])%, P = 0.010). Protein digestion and absorption was lower in COPD (0.647 (95% CI [0.588, 0.705]) vs. 0.823 (95% CI [0.737, 0.909]), P = 0007), and impairment greater in patients with dyspnea (P = 0.038), exacerbations in preceding year (P = 0.052), and reduced transcutaneous oxygen saturation (P = 0.051), and was associated with reduced physical activity score (P = 0.016) and lower quality of life (P = 0.0007). Plasma acetate concentration was reduced in COPD (41.54 (95% CI [35.17, 47.91]) vs. 80.44 (95% CI [54.59, 106.30]) mmol/L, P = 0.001) suggesting perturbed intestinal microbial metabolism. Conclusions: We conclude that intestinal dysfunction is present in COPD, worsens with increasing disease severity, and is associated with reduced quality of life. (c) 2020 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.
Original languageEnglish
Pages (from-to)2270-2277
Number of pages8
JournalClinical Nutrition
Volume40
Issue number4
DOIs
Publication statusPublished - 1 Apr 2021

Keywords

  • Comorbidity
  • Gut dysfunction
  • Protein digestion and absorption
  • Stable tracer kinetics
  • Oral sugar tests
  • Short-chain fatty acids
  • GASTROINTESTINAL SYMPTOMS
  • PROTEIN
  • PERMEABILITY
  • COPD
  • PREVENTION

Cite this